

Clinical Pharmacy Program Guidelines for CGRP

Program	Prior Authorization
Medication	Aimovig (erenumab), fremanezumab, galcanezumab
Issue Date	3/2018
Pharmacy and Therapeutics Approval Date	3/2018
Effective Date	5/2018

1. Background:

Pending

2. Coverage Criteria:

<p>A. <u>Episodic Migraine</u></p> <p>1. <u>Initial Therapy</u></p> <p>a. CGRP will be approved based upon all of the following criteria:</p> <p>(1) Diagnosis of episodic migraines with both of the following:</p> <p style="margin-left: 40px;">(a) Less than 15 headache days per month</p> <p style="margin-left: 40px;">(b) Patient has 4 to 14 migraine days per month</p> <p style="text-align: center;">-AND-</p> <p>(2) Prescribed by or in consultation with one of the following specialists:</p> <p style="margin-left: 40px;">(a) Neurologist</p> <p style="margin-left: 40px;">(b) Pain Specialist</p> <p style="text-align: center;">-AND-</p> <p>(3) History of failure (after a trial of at least two months), contraindication, or intolerance to two of the following prophylactic therapies from the list below:</p> <p style="margin-left: 40px;">(a) amitriptyline (Elavil)</p> <p style="margin-left: 40px;">(b) atenolol (Tenormin)</p>
--

- (c) divalproex sodium (Depakote/Depakote ER)
- (d) metoprolol (Lopressor/Toprol XL)
- (e) nadolol (Corgard)
- (f) propranolol (Inderal)
- (g) timolol (Blocadren)
- (h) topiramate (Topamax)
- (i) venlafaxine (Effexor)

Authorization will be issued for 3 months.

2. Reauthorization

a. **CGRP** will be approved based on **both** of the following criteria:

(1) Prescribed by or in consultation with one of the following specialists:

- (a) Neurologist
- (b) Pain Specialist

-AND-

(2) Patient has experienced a positive response to therapy, demonstrated by a reduction in headache frequency and/or intensity

Authorization will be issued for 12 months.

B. Chronic Migraine

1. Initial Therapy

a. **CGRP** will be approved based upon **all** of the following criteria:

(1) Diagnosis of chronic migraines with **both** of the following:

- (a) Greater than or equal to 15 headache days per month
- (b) Greater than or equal to 8 migraine days per month

-AND-

(2) Prescribed by or in consultation with one of the following specialists:

- (a) Neurologist
- (b) Pain Specialist

-AND-

(3) History of failure (after a trial of at least two months), contraindication, or intolerance to **two** of the following prophylactic therapies from the list below:

- (a) amitriptyline (Elavil)
- (b) atenolol (Tenormin)
- (c) Botox (Onabotulinumtoxin A)
- (d) divalproex sodium (Depakote/Depakote ER)
- (e) metoprolol (Lopressor/Toprol XL)
- (f) nadolol (Corgard)
- (g) propranolol (Inderal)
- (h) timolol (Blocadren)
- (i) topiramate (Topamax)
- (j) venlafaxine (Effexor)

Authorization will be issued for 3 months.

2. Reauthorization

a. **CGRP** will be approved based on **both** of the following criteria:

(1) Prescribed by or in consultation with one of the following specialists:

- (a) Neurologist
- (b) Pain Specialist

-AND-

(2) Patient has experienced a positive response to therapy, demonstrated by a reduction in headache frequency and/or intensity

Authorization will be issued for 12 months.

3. References:

1. International Headache Society (IHS); Headache Classification Committee. The International Classification of Headache Disorders, 3rd edition (beta version). Cephalalgia. 2013; 33: 629-808.
2. Silberstein SD, Holland S, Freitag F, et al. Evidence-based guideline update: pharmacologic treatment for episodic migraine prevention in adults: report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society. Neurology. 2012 Apr 24;78(17):1337-45.

Confidential and Proprietary, © 2018 UnitedHealthcare Services Inc.

3. Simpson DM, Hallett M, Ashman EJ, et al. Practice guideline update summary: Botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache: Report of the Guideline Development Subcommittee of the American Academy of Neurology. *Neurology*. 2016 May 10;86(19):1818-26.

Program	Prior Authorization
Change Control	
Date	Change
3/2018	New Program